[{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Chinese Academy of Medical Sciences","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese Academy of Medical Sciences \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chinese Academy of Medical Sciences \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase IV","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Wuhan Union Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Elevar Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apatinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elevar Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Rivoceranib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
